Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

There are a few clues about a mystery backer for Anne Wojcicki's bankruptcy bid for 23andMe, and they point toward a software ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

The FDA may be facing a 4% cut to its overall budget courtesy of the Trump administration, but that hasn’t stopped the agency ...

Rating upgraded from 85 to 91 Tuesday. Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

H1 picked up provider data management software company Ribbon Health to broaden its reach into the health plan, provider ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Zydus Lifesciences Ltd. expands its global biologics CDMO capabilities by acquiring Agenus Inc.'s U.S.-based facilities. The ...

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...